The investigators investigated the efficacy and safety of High Flow Nasal Cannula (HFNC) at different flow rates compared to non-invasive ventilation (NIV) in patients presenting to the emergency department (ED) with acute exacerbations of Chronic obstructive pulmonary disease (COPD) who did not respond adequately to bronchodilator therapy and continued to exhibit hypercapnic respiratory failure. Specifically, the investigators tested the hypothesis that HFNC would be more effective at reducing partial pressure of carbon dioxide (PaCO2) levels and hospital stay duration and would be associated with greater patient comfort than NIV.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in pH in arterial blood gas before vs. after treatment
Timeframe: at 30, 60, and 120 minutes relative to baseline
Changes in PaCO2 in arterial blood gas before vs. after treatment
Timeframe: at 30, 60, and 120 minutes relative to baseline
Changes in lactate in arterial blood gas before vs. after treatment
Timeframe: at 30, 60, and 120 minutes relative to baseline
Changes in bicarbonate in arterial blood gas before vs. after treatment
Timeframe: at 30, 60, and 120 minutes relative to baseline